TY - JOUR
T1 - Severity and duration of dysglycemia and brain injury among patients with neonatal encephalopathy
AU - Kamino, Daphne
AU - Widjaja, Elysa
AU - Brant, Rollin
AU - Ly, Linh G.
AU - Mamak, Eva
AU - Chau, Vann
AU - Moore, Aideen M.
AU - Williams, Tricia
AU - Tam, Emily W.Y.
N1 - Funding Information:
Canadian Institutes for Health Research, National Institutes of Health, and SickKids Foundation.VC reports research funding from Xeon Pharmaceuticals Inc. outside the submitted work. EW reports research funding from Ontario Brain Institute and Pediatric Epilepsy Research Foundation outside of the submitted work, and leadership in the American Society of Neuroradiology and the Canadian League Against Epilepsy. TW reports leadership in the American Academy of Clinical Neuropsychology. EWYT reports research funding from SickKids Foundation and UCB Biopharma outside the submitted work, speaker fees from Columbia University in New York and the Children's Hospital of Fudan University in Shanghai, expert testimony fees from Bennett Jones LLP and Gowling WLG, and leadership roles in the Pediatric Academic Societies Meeting and the Newborn Brain Society. All other authors declare no competing interests.This work was supported by the Canadian Institutes for Health Research [MOP-133710, PJT-166076], the National Institutes of Health [R01 HD101419], and the SickKids Foundation awarded to EWYT. Continuous glucose monitors were provided by Medtronic Canada. The authors thank the families and children who have participated in this study. The authors also thank the NOGIN research team, including the SickKids Acute Care Transport Services team for recruiting study subjects, and Ashley Coppin for transporting the neonates to/from the MRI scanner and clinical data collection.
Funding Information:
This work was supported by the Canadian Institutes for Health Research [ MOP-133710 , PJT-166076 ], the National Institutes of Health [ R01 HD101419 ], and the SickKids Foundation awarded to EWYT. Continuous glucose monitors were provided by Medtronic Canada. The authors thank the families and children who have participated in this study. The authors also thank the NOGIN research team, including the SickKids Acute Care Transport Services team for recruiting study subjects, and Ashley Coppin for transporting the neonates to/from the MRI scanner and clinical data collection.
Publisher Copyright:
© 2023 The Authors
PY - 2023/4
Y1 - 2023/4
N2 - Background: Evidence is needed to inform thresholds for glycemic management in neonatal encephalopathy (NE). We investigated how severity and duration of dysglycemia relate to brain injury after NE. Methods: A prospective cohort of 108 neonates ≥36 weeks gestational age with NE were enrolled between August 2014 and November 2019 at the Hospital for Sick Children, in Toronto, Canada. Participants underwent continuous glucose monitoring for 72 h, MRI at day 4 of life, and follow-up at 18 months. Receiver operating characteristic curves were used to assess the predictive value of glucose measures (minimum and maximum glucose, sequential 1 mmol/L glucose thresholds) during the first 72 h of life (HOL) for each brain injury pattern (basal ganglia, watershed, focal infarct, posterior-predominant). Linear and logistic regression analyses were used to assess the relationship between abnormal glycemia and 18-month outcomes (Bayley-III composite scores, Child Behavior Checklist [CBCL] T-scores, neuromotor score, cerebral palsy [CP], death), adjusting for brain injury severity. Findings: Of 108 neonates enrolled, 102 (94%) had an MRI. Maximum glucose during the first 48 HOL best predicted basal ganglia (AUC = 0.811) and watershed (AUC = 0.858) injury. Minimum glucose was not predictive of brain injury (AUC <0.509). Ninety-one (89%) infants underwent follow-up assessments at 19.0 ± 1.7 months. A glucose threshold of >10.1 mmol/L during the first 48 HOL was associated with 5.8-point higher CBCL Internalizing Composite T-score (P = 0.029), 0.3-point worse neuromotor score (P = 0.035), 8.6-fold higher odds for CP diagnosis (P = 0.014). While the glucose threshold of >10.1 mmol/L during the first 48 HOL was associated with higher odds of the composite outcome of severe disability or death (OR 3.0, 95% CI 1.0–8.4, P = 0.042), it was not associated with the composite outcome of moderate-to-severe disability or death (OR 0.9, 95% CI 0.4–2.2, P = 0.801). All associations with outcome lost significance after adjusting for brain injury severity. Interpretation: Maximum glucose concentration in the first 48 HOL is predictive of brain injury after NE. Further trials are needed to assess if protocols to control maximum glucose concentrations improve outcomes after NE. Funding: Canadian Institutes for Health Research, National Institutes of Health, and SickKids Foundation.
AB - Background: Evidence is needed to inform thresholds for glycemic management in neonatal encephalopathy (NE). We investigated how severity and duration of dysglycemia relate to brain injury after NE. Methods: A prospective cohort of 108 neonates ≥36 weeks gestational age with NE were enrolled between August 2014 and November 2019 at the Hospital for Sick Children, in Toronto, Canada. Participants underwent continuous glucose monitoring for 72 h, MRI at day 4 of life, and follow-up at 18 months. Receiver operating characteristic curves were used to assess the predictive value of glucose measures (minimum and maximum glucose, sequential 1 mmol/L glucose thresholds) during the first 72 h of life (HOL) for each brain injury pattern (basal ganglia, watershed, focal infarct, posterior-predominant). Linear and logistic regression analyses were used to assess the relationship between abnormal glycemia and 18-month outcomes (Bayley-III composite scores, Child Behavior Checklist [CBCL] T-scores, neuromotor score, cerebral palsy [CP], death), adjusting for brain injury severity. Findings: Of 108 neonates enrolled, 102 (94%) had an MRI. Maximum glucose during the first 48 HOL best predicted basal ganglia (AUC = 0.811) and watershed (AUC = 0.858) injury. Minimum glucose was not predictive of brain injury (AUC <0.509). Ninety-one (89%) infants underwent follow-up assessments at 19.0 ± 1.7 months. A glucose threshold of >10.1 mmol/L during the first 48 HOL was associated with 5.8-point higher CBCL Internalizing Composite T-score (P = 0.029), 0.3-point worse neuromotor score (P = 0.035), 8.6-fold higher odds for CP diagnosis (P = 0.014). While the glucose threshold of >10.1 mmol/L during the first 48 HOL was associated with higher odds of the composite outcome of severe disability or death (OR 3.0, 95% CI 1.0–8.4, P = 0.042), it was not associated with the composite outcome of moderate-to-severe disability or death (OR 0.9, 95% CI 0.4–2.2, P = 0.801). All associations with outcome lost significance after adjusting for brain injury severity. Interpretation: Maximum glucose concentration in the first 48 HOL is predictive of brain injury after NE. Further trials are needed to assess if protocols to control maximum glucose concentrations improve outcomes after NE. Funding: Canadian Institutes for Health Research, National Institutes of Health, and SickKids Foundation.
KW - Hyperglycaemia
KW - Hypoglycemia
KW - Hypoxic ischemic encephalopathy
KW - MRI
KW - Neonatal encephalopathy
KW - Neonatal neurology
KW - Neurodevelopmental outcomes
UR - http://www.scopus.com/inward/record.url?scp=85153290116&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85153290116&partnerID=8YFLogxK
U2 - 10.1016/j.eclinm.2023.101914
DO - 10.1016/j.eclinm.2023.101914
M3 - Article
AN - SCOPUS:85153290116
SN - 2589-5370
VL - 58
JO - EClinicalMedicine
JF - EClinicalMedicine
M1 - 101914
ER -